GSK discontinues Promacta study on blood-clot concerns
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has discontinued its Phase III ELEVATE study of oral thrombopoietin receptor agonist Promacta (eltrombopag) due to an increased incidence of thrombosis in patients with thrombocytopenia due to chronic liver disease receiving the drug.